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Context: Peutz Jeghers Syndrome (PJS) is an autosomal dominant disorder which arises as a con-
sequence of mutations in the STK11 gene that encodes LKB1. PJS males often have estrogen excess
manifesting as gynecomastia and advanced bone age. We and others have previously described an
increase in testicular aromatase expression in PJS patients. However, the underlying mechanism has
not yet been explored.
Objective: The aim of this study was to characterize the role of LKB1 in regulating the expression
of aromatase in boys with PJS via signaling pathways involving AMPK and CRTCs.
Patients: We studied testicular biopsies from two boys with STK11 mutations; a 13-year-old boy and
an unrelated 4-year-old boy with prepubertal gynecomastia and advanced bone age, as well as
breast tissue from the 13-year-old boy.
Results: Loss of heterozygosity (LOH) of STK11, measured by the absence of LKB1 immunofluo-
rescence, was observed in Sertoli cells of abnormal cords of testis samples from affected individuals.
This was associated with loss of p21 expression and decreased phosphorylation of AMPK, known
downstream targets of LKB1, as well as the increased expression of aromatase. Similar results of low
LKB1 expression in cells expressing aromatase were observed in the mammary epithelium from one
of these individuals. Nuclear expression of the CRTC proteins, potent stimulators of aromatase and
known to be inhibited by AMPK, was significantly correlated with aromatase.
Conclusions: LOH of the STK11 gene leads to an increase in aromatase expression associated with
an increase in CRTC nuclear localization, thereby providing a mechanism whereby PJS results in
increased endogenous estrogens in affected males.
Peutz Jeghers Syndrome (PJS) is an autosomal dominantcondition characterized by gastrointestinal (GI)
harmartomatous polyps and mucocutaneous pigmenta-
tion (1). Prepubertal males may have estrogen excess man-
ifesting as gynecomastia and an advanced bone age that is
typically associated with Sertoli cell lesions of the testes of
affected individuals (2–4). Gynecomastia in prepubertal
boys is rare and most often arises as a consequence of
endocrine abnormalities involving the increased endoge-
nous production of estrogens within the testis or at ex-
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tragonadal sites (5). Aromatase is the key enzyme respon-
sible for the conversion of androgens to estrogens and
breast growth in boys is a direct result of the dysregulation
of the balance between androgens and estrogens (6).
Most PJS cases occur as a consequence of mutations in
the Serine Threonine Kinase 11 (STK11) gene (1, 7). These
range from point mutations, located in the kinase domain
and C-terminal domain, to more substantial alterations
including complete truncations of the catalytic domain.
STK11 encodes the Liver kinase B1 (LKB1) protein. LKB1
is a tumor suppressor through its interaction with p53 to
increase the expression of cell cycle arrest proteins includ-
ing p21, and is a key regulator of energy homeostasis by
directly phosphorylating and activating AMP-activated
protein kinase (AMPK) (7). We have established a link
between LKB1 and aromatase in the female breast involv-
ing cyclic AMP-responsive element binding protein-regu-
lated transcription coactivator 2 (CRTC2) (8). By directly
phosphorylating AMPK, LKB1 inhibits the nuclear trans-
location of CRTC2 within breast adipose tissue and de-
creases the cAMP-dependent activation of aromatase pro-
moter PII. In breast cancer, tumor-derived inflammatory
factors, which include prostaglandin E2, decrease the ex-
pression and activity of LKB1 causing the increased nu-
clear localization of CRTC2 and increased expression of
aromatase. Three CRTCs exist, but the role of CRTC1,
CRTC2, and CRTC3 in the regulation of aromatase ex-
pression in the testis has not yet been established. We pos-
tulated that similar events account for prepubertal gyne-
comastia observed in PJS.
The aim of this study was to characterize the role of
LKB1 in regulating the expression of aromatase in the
testis of two boys with PJS via signaling involving pAMPK
and CRTC1, CRTC2, and CRTC3, as well as examine this
relationship in breast tissue.
Case Reports
Patient one
Patient one presented initially at 1 year of age with
bleeding per rectum associated with GI hamartomatous
polyps. During polypectomy he was noted to have hyper-
pigmented macules of the lips and oral mucosa, support-
ing a provisional diagnosis of PJS. There was no family
history suggesting PJS. The patient was lost to follow up
for some years but represented with per rectal bleeding at
nine years of age. He was referred for endocrine assess-
ment at 12 years five months of age for investigation of
prepubertal gynecomastia characterized by firm non-
tender breast tissue corresponding to Tanner stage three,
which had developed over the previous two and a half
years. Breast tissue was palpable beneath prominent are-
ola bilaterally and testes measured 4 ml bilaterally. At the
chronological age of 12 years and five months bone age
was advanced corresponding closest to the male standard
for 14 years in Greulich and Pyle (standard deviation
10.5 months). Serum estradiol levels were elevated at 30
pmol/l (9). A testicular ultrasound identified microlithiasis
with no evidence of testicular tumors, consistent with pre-
vious PJS reports (10). The patient was offered treatment
with an aromatase inhibitor but declined this medical ther-
apy. Mastectomy and a biopsy of the testis were performed
at 13 years 3 months of age. A heterozygous mutation in
STK11 (910delC) was identified on analysis of genomic
DNA at 12.5 years of age confirming the clinical diagnosis
of PJS. Height at 13 years 5 months of age was 171 cm
(height standard deviation score (SDS) 1.3). Final adult
height at 18.1 year of age was 183 cm (SDS 1.0).
Patient two
Patient two was referred for assessment of prepubertal
gynaecomastia at 4 years of age. The available interval of
follow up is approximately 6 years from first presentation.
There was a family history of PJS associated with a known
STK11 mutation, c.180CA p.Tyr60X (11), affecting his
mother. The same mutation was identified in gDNA from
Patient two as part of endocrine investigations confirming
PJS at 4 years of age. Height at a chronological age of 4
years and one month of age was 112.5 cm (SDS 2.3). The
associated bone age corresponded nearest to the male
standard for five years in Greulich and Pyle (standard de-
viation  6.6 months). Growth velocity prior to initial
presentation is not known. Letrozole (a third generation
oral aromatase inhibitor) was commenced at 4 years of age
to treat gynaecomastia and reduce the rate of skeletal mat-
uration. Aromatase inhibition therapy continued without
interruption until 10 years of age, the dose throughout this
interval was 2.5 mg/d. Growth velocity averaged 4.45 cm
per year during the 6 year period of letrozole therapy. At
ten years two months of age, his height was 139.2 cm (SDS
0.1). At 10 years chronological age, bone age corre-
sponded closest to the male standard for 10 years in Greu-
lich and Pyle. Serum estradiol levels were assayed at four
years of age prior to initiation of letrozole treatment and
again at nine years of age while on letrozole therapy. On
both occasions serum estradiol levels were below the limits
of detection. Estrone levels were not determined on either
occasion. On ultrasound examination at four years six
monthsof age, testeswere enlarged,3.5mlon the right and
2.8 ml on the left. Microlithiasis was identified. Bilateral
mastectomy and biopsy of the testis were performed at five
years one month of age. Annual testicular ultrasound find-
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ings did not change significantly over the follow-up period
of six years.
Informed consent for publication of these case studies
was obtained according to the institutional guidelines of
Princess Margaret Hospital for Children’s Human Re-
search Ethics Committee and the Southern Health Human
Research Ethics Committee.
Materials and Methods
Genetic and Biochemical studies
In the setting of a mutation search of STK11, denaturing high
pressure liquid chromatography (DHPLC) analysis was per-
formed to screen for STK11 mutations. Genomic sequencing was
performed to confirm any mutation.
Testing for a known familial mutation
was performed by restriction enzyme di-
gest. Serum estradiol was assayed by Sie-
mens Coat-A-Count Estradiol, Siemens
Health Care Diagnostics Inc, Los Ange-
les, USA. This is a sensitive estradiol as-
say that uses a Double Antibody Estra-
diol sequential radioimmunoassay
(RIA). The lower limit of detection is 20
pmol/l. For Patient two, an additional
measurement was performed at age 9
years using Liquid Chromatography–
Tandem Mass Spectrometry (Mayo
Clinic Laboratories) where the lower
limit of detection is 10 pg/ml (or 36.7
pmol/l).
Detection of LKB1 expression
and activity
The LKB1 antibody (Cat #3050, Cell
Signaling) used in Western blotting and
immunofluorescence binds to a region
between amino acids 340 and 450 of hu-
man LKB1, indicating that it will not de-
tect the proteins associated with the
germline mutations identified for both
patients. To determine the effect of mu-
tation on protein expression and stabil-
ity, mutations were introduced into a
construct containing the open reading
frame with in-frame flag tag at the 5 end
using site-directed mutagenesis. Proteins
were overexpressed in COS-7 cells and
detected by Western blotting using anti-
flag (Cat #2368, Cell Signaling) or anti-
LKB1 antibodies. Proteins were visual-
ized with the Odyssey infrared imaging
system (Licor Biosciences, Lincoln, NE)
after conjugation with a secondary anti-
body (Alexa Fluor 680 goat antirabbit
antibody, Invitrogen, Melbourne, Aus-
tralia). Protein stability was also assessed
by Western blotting of protein extracts
from cells treated for zero, four, and
eight hours with 200 M cycloheximide (CHX) to inhibit pro-
tein translation. Aromatase promoter PII reporter assays were
performed as previously described (8) to determine the effect of
CRTC1, CRTC2, and CRTC3 on aromatase expression. Briefly,
COS-7 cells were seeded at 2  105 per well in six-well plates and
incubated overnight prior to transfection. Cells were cotrans-
fected with a promoter II-reporter construct, and expression vec-
tors for CRTCs and LKB1 using Fugene6 (Roche applied science,
NSW, Australia) followed by serum-starvation for 24 hours with
serum-free media containing 0.1% BSA. After starvation, lu-
ciferase reporter assays were performed using the Dual-Glo lu-
ciferase assay system (Promega, WI, USA) as described by the
manufacturer. The effect of LKB1 on the CRTC-mediated acti-
vation of PII was also assessed.
Figure 1. Testis cord structure and aromatase immunofluorescence of healthy prepubertal, and
PJS testis samples. Panels A, C & E: H&E staining was performed to assess hitopathology and
identify abnormal cords in PJS patient samples (C and E, black arrows). Panel B, D & F: Aromatase
immunofluorescence (green) was strongest in abnormal cords from PJS patient samples (D & F,
white arrows). Somatic cell marker, GATA4, appears pink; nuclear stain, TOPRO3, appears blue.
Scale bar represents 20 m.
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Histology
Testicular biopsies were obtained from Patient one and Pa-
tient two when they were aged 13 and four, respectively, and
compared to normal archival testicular tissue from a four year-
old boy. Breast tissue from Patient one was obtained at five years
of age and compared to breast tissue derived from adult male and
healthy and tumor-bearing female. Formalin-fixed paraffin-em-
bedded tissue, sectioned (5 m), was stained using hematoxylin
and eosin (H&E) or immunofluorescence was performed using
a protocol adapted from Tarulli et al (12). Immunohistochem-
istry for aromatase on breast tissue was performed using the
Vectastain ABC-HP kit and 3,3-diaminobenzidine tetrahydro-
chloride (DAB, Sigma-Aldrich, USA) as a substrate, adapted
from Samarajeewa et al (13). Antibodies used were as follows:
LKB1 (Cat #3050), CRTC1 (Cat #2501), CRTC2 (Cat #3826),
CRTC3 (Cat #2768), pAMPK (Cat #2535s), and p21 (Cat
#2947s), and were purchased from Cell Signaling. Somatic cell
nuclear marker GATA4 antibody (Cat #14–9980) was pur-
chased from eBioscience. Aromatase mouse monoclonal primary
antibody 677 was obtained from Prof. Dean P. Edwards (Baylor
College of Medicine). Secondary antibodies and TOPRO3 nu-
clear stain (Cat #T3605) were purchased from Invitrogen.
Statistical analyses
Reporter assays and Western blotting were performed at least
three times and results are displayed as mean  SEM. Analysis
was performed by a two-tailed Student’s t test using GraphPad
Prism version five. Statistical significance was identified with P 
.05. For Figure 2F, statistically significant differences were iden-
tified using different letters.
Results
Abnormal testis cords and heterogeneous
aromatase staining
Both patients displayed similar morphology upon his-
topathological assessment of testicular biopsies. Notably,
abnormal cords with thickening of the basement mem-
brane and the peritubular stroma, and enlarged cells con-
taining ovoid nuclei, wispy cytoplasm and prominent cen-
tral nucleoli were observed (Figure 1C & E). Invaginations
of stroma into the tubular epithelium were also recognized
in some areas. The surrounding cords showed evidence of
increased Sertoli cells with occasional germ cells. These
histopathological findings are consistent with the Sertoli
cell proliferations found in previously published cases of
PJS (3). VASA staining confirmed the presence of germ
cells within the normal cords (data not shown). No evi-
dence of malignancy was discovered. Abnormal cords
contained cells positive for GATA4, a somatic cell marker
that is specific for Sertoli cells within cords, which also
displayed intense staining for aromatase (Figure 1D & F)
compared to healthy prepubertal testicular tissue (Figure
1B) and normal cords within PJS patient samples. Upon
closer examination, aromatase immunoreactivity was
found to be heterogeneous within abnormal cords.
Effect of mutations on LKB1 protein stability and
expression within cords
A heterozygous mutation in the STK11 gene was iden-
tified for each patient. For Patient one, a frameshift mu-
tation p.Arg304Glyfs*32 was identified. As a result, the
LKB1 protein has complete loss of function of the C-ter-
minal domain and is truncated (Figure 2A). The trunca-
tion of this protein with predicted molecular weight of 38
kDa was confirmed when the protein was overexpressed
and visualized by Western blot using an antiflag antibody
(Supplementary Figure 1A). Stability assays demonstrate
that this mutation significantly impairs protein stability
when compared to the full-length protein (Figure 2C). For
Patient two, a nonsense mutation was identified at
c.180CA p.Tyr60X. This mutation leads to complete
loss of the kinase and C-terminal domains (Figure 2A) and
the protein, with predicted molecular weight of 8 kDa, is
undetectable in cells transfected with a flag-tagged con-
struct (Supplementary Figure 1A). Full length LKB1 pro-
tein expression, as demonstrated by the presence of LKB1
immunofluorescence, was present in cells within normal
cords from sections from Patient one (Figure 2B). Abnor-
mal cords displayed heterogeneous expression of LKB1
with some cells displaying intense LKB1 staining (Figure
2B, white arrow) and others with apparent loss of
heterozygosity (LOH), where LKB1 staining was absent
(Figure 2B, black arrow). Cells within abnormal cords
which displayed LKB1 staining had low to undetectable
expression of aromatase. This was evident from the lack of
yellow staining. STK11 LOH was also examined in patient
sections by staining for LKB1 downstream targets,
pAMPK and p21 (Figure 2D & E, respectively). Staining
for pAMPK revealed strong punctate expression localized
to a single region within the cell cytoplasm, whereas p21
staining was predominantly nuclear. In cells where
pAMPK and p21 were present (Figure 2D & E, respec-
tively, white arrows), aromatase staining was low to un-
detectable. Conversely, cells which displayed intense aro-
matase staining had low to undetectable staining for
LKB1, p21, and pAMPK (Figure 2B, D, E, respectively,
black arrows). Results for Patient two were similar (Sup-
plementary Figure 1B, C &D).
LKB1 inhibits the CRTC-mediated activity of
aromatase PII and increased aromatase expression
is associated with an increase in CRTC nuclear
staining
Results from reporter assays demonstrated that
CRTC1, CRTC2, and CRTC3 significantly increase the
activity of aromatase promoter PII in vitro (Figure 2F; blue
bars) with CRTC3 causing the most dramatic effect. Full
length LKB1 significantly inhibited the CRTC-mediated
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activation of PII (Figure 2F; red bars). Staining for CRTC1
and CRTC3 was detectable by immunofluorescence in Pa-
tient one testes sections within normal and abnormal
cords (Figure 3A & E, respectively). CRTC2 staining was
undetectable (Figure 3C). CRTC1 and CRTC3 subcellular
localization was associated with intensity of aromatase
staining (Figure 3A & E), where cells
with high nuclear CRTC immunore-
activity had high aromatase staining
(filled arrows) and cells with weak
nuclear CRTC immunoreactivity
had low aromatase staining (empty
arrows). Quantification of fluores-
cence intensity revealed a significant
positive correlation between average
intensity of aromatase and nuclear
CRTC1 and CRTC3 (Supplemen-
tary Figure 3). A positive correlation
between nuclear CRTC3 and aroma-
tase was also found for Patient two
(Supplementary Figure 2).
Aromatase is increased in
epithelial cells with LKB1 LOH
from PJS breast tissue
Immunohistochemistry demon-
strated that aromatase is expressed
in PJS breast tissue from Patient one
(Figure 4A). Aromatase immunore-
activity was higher than that of tissue
obtained from non-PJS gynecomas-
tia and healthy female breast (Figure
4C and D, respectively) and was
comparable to levels seen in female
postmenopausal breast cancer (Fig-
ure 4B). Multichannel confocal im-
ages also demonstrated that similar
to testicular tissue, aromatase immu-
noreactivity was undetectable in
cells where LKB1 was high, and ele-
vated in cells were apparent LKB1
LOH had occurred (Figure 4E). All
three CRTCs were detectable in PJS
breast tissue (Figure 4F-H) and nu-
clear CRTC fluorescence intensity
was significantly positively corre-
lated with aromatase average inten-
sity (Supplementary Figure 3).
Discussion
This report describes a mechanism
which explains the clinical findings of prepubertal gyne-
comastia in two unrelated male patients. Namely, in-
creased expression of aromatase resulting from nuclear
localization of CRTC proteins due to LOH of the STK11
gene and decreased phosphorylation of AMPK.
The age of onset and severity of bilateral breast en-
Figure 2. In vitro and in vivo assessment of LKB1 expression and activity (A) Diagram of the
location of STK11 mutations on the primary structure of the LKB1 protein. Asterisks represent
location of identified mutation and lines represent location of stop codon for PJS Patient one
(red) and Patient two (blue). (B) Immunofluorescence for LKB1 (green) and aromatase (red). (C)
Stability assay for PJS1 and PJS2 LKB1 proteins. Western blot (top) and densitometric analysis
(bottom) of LKB1 protein abundance of full length (FL), Patient one (PJS#1) and Patient two
(PJS#2) proteins after cycloheximide (CHX) treatment to inhibit protein translation. (D)
Immunofluorescence for pAMPK (green) and aromatase (red). (E) Immunofluorescence for p21
(green) and aromatase (red). (F) Reporter assay demonstrating that CRTC1, CRTC2, and CRTC3
increase aromatase promoter II (PII) activity (blue bars) and that full length LKB1 significantly
inhibits the CRTC-mediated activation of PII (red bars). Different letters denote statistical
differences (P  .05) between groups. Three comparisons were made i) between transfected and
nontransfected LKB1 (red vs blue bars) ii) between CRTCs tranfected without LKB1 (blue bars)
and iii) between CRTCs transfected with LKB1 (red bars). Immunofluorescence images are
presented for Patient one. Patient two images available in Supplementary 1. Blue fluorescence
represents nuclear stain TOPRO3. Scale bar represent 20 m. NRD: N-terminal regulatory
domain, CRD: C-terminal regulatory domain.
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largement were different in each patient. Although they
both developed harmatomatous polyps at an early age,
prepubertal gynecomastia was evident in Patient two at
four years of age and developed from approximately eight
years of age in Patient one. The mutation identified for
Patient two (c.180CA) causes the complete loss of the
kinase and C-terminal regulatory domains, and the pro-
tein is undetectable when overexpressed, suggesting that it
is rapidly degraded. This boy had a much earlier onset of
breast enlargement compared with Patient one, who has a
mutation which causes loss of the C-terminal domain with
significantly impaired protein stability, raising the possi-
bility of a correlation between the genotype and pheno-
type. Function of the C-terminal regulatory domain of
LKB1 is not yet fully understood.
Truncation of this domain does not
appear to affect the ability of LKB1
to phosphorylate AMPK in vitro or
cause cell cycle arrest (14). Nonethe-
less, several mutations which lead to
early stop codons or frameshifts
within the C-terminal regulatory do-
main have been identified in patients
with PJS or sporadic cancers (7), sug-
gesting that the impaired stability of
the Patient one protein may account,
at least in part, for the observed PJS
phenotype. A study by Nony et al
suggests that proteosomal, rather
than lysosomal, degradation ac-
counts for LKB1 protein degrada-
tion (15). On the other hand, the im-
pact of C-terminal mutations on
LKB1 mRNA stability has also been
proposed. It has been suggested that
truncated forms of LKB1 may be ex-
pressed at very low levels in vivo due
to nonsense-mediated decay, a
mechanism which causes the degra-
dation of mRNA containing prema-
ture stop codons (16, 17). LKB1 and
aromatase expression was heteroge-
neous in abnormal testis cords from
both PJS patients. Cells expressing
full length LKB1 and its downstream
targets pAMPK and p21 did not ex-
press aromatase. Reciprocally, Ser-
toli cells displaying intense aroma-
tase staining had low to undetectable
levels of LKB1, pAMPK, and p21.
This suggests that impaired LKB1
protein expression is necessary for
the abnormal induction of aroma-
tase within the testis. Bardeesy et al (18) have suggested
that LOH of STK11 is necessary for the development of
PJS-like features in LKB1/- mice. These animals which
develop GI polyps, similar to that in PJS, had either lost the
wild-type LKB1 allele or had completely lost LKB1 ex-
pression in cells isolated from the polyps. This was also
demonstrated to be the case for LKB1 /- mice which
develop hepatocellular carcinomas, where LKB1 mRNA
and protein expression were absent (19). Loss of the ho-
mologous normal allele of LKB1/STK11 has also been
described in humans, including one report demonstrating
LOH in aggressive breast cancer (20). Based on our im-
munofluorescence data, we speculate that decreased ex-
Figure 3. Localization of CRTC1, CRTC2 and CRTC3 in relation to aromatase in PJS testis
Immunofluorescence for CRTC1 (green, A, B), CRTC2 (green, C, D), CRTC3 (green, E, F) and
aromatase (red, A, C, E) was examined in Patient one testis sections. Blue fluorescence represents
nuclear stain TOPRO3. Scale bar represent 20 m. Right column (B, D, F) contains green staining
alone to permit visualization of subcellular localization. Contours of cells were drawn in white
and contours of nuclei were drawn in blue.
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pression of LKB1 is due to STK11 LOH within human
testicular Sertoli cells of PJS patients, and that this leads to
an increase in aromatase expression and the development
of abnormal cords.
Although serum estradiol levels were not elevated in
Patient two (both prior to and during letrozole treatment)
and only mildly elevated in Patient one, both displayed
signs of estrogen excess with advanced bone age and bi-
lateral prepubertal breast enlargement. Neither were
obese individuals. Increased gonadal expression of aro-
matase has been demonstrated in PJS patients and testic-
ular expression of aromatase has been suggested to be the
cause of gynecomastia in prepubertal boys with PJS (21–
23). Lefevre et al noted normal plasma estrogen levels in
one of their patients with prepubertal gynaecomastia, and
varying levels of plasma estradiol in their review of the
literature identifying 22 patients with PJS and testicular
tumors (24).
Although estrone levels were not assessed in either of
our patients, it is possible that increased testicular aroma-
tase activity may have resulted in elevated levels of other
estrogens, eg, estrone, as has been observed in kindred
with gain of function aromatase mutations (25, 26). Nei-
ther of our patients had a bone biopsy, it is conceivable
that the bone age advancement observed in these two pa-
tients may have resulted in part from a local autocrine
action of increased aromatase activity (27, 28). Normal-
ization of bone age and growth in Patient two who was
treated with an aromatase inhibitor despite low serum
estradiol levels raises the possibility of local inhibition of
aromatase activity in bone to account for these clinical
observations (29, 30).
We have shown that LKB1 is a negative regulator of
aromatase in the female breast (8). It is conceivable that
altered expression of LKB1 in breast tissue also contrib-
utes to breast enlargement observed in these two patients
and findings presented in the present manuscript support
that hypothesis. In particular, our results suggest that
LKB1 LOH also occurs in the mammary epithelium and
this is associated with the increased nuclear expression of
CRTC proteins and aromatase. A mechanism whereby
this occurs involves LKB1 activating AMPK by directly
phosphorylating the alpha subunit at Thr172. As a result,
AMPK phosphorylates CRTCs, coactivators of CREB and
potent stimulators of aromatase expression, and causes
their cytoplasmic sequestration via interactions with 14–
3–3 proteins. Our previous research in the breast has dem-
onstrated that decreased expression of LKB1 is sufficient
for CRTC2 to enter the nucleus where it can activate the
promoter PII-dependent transcription of aromatase (8).
Interestingly, it is also aromatase promoter PII which is
used to drive gonadal expression of aromatase, and we
and others have demonstrated that PII-specific transcripts
are increased in the PJS testis (31, 32).
The luciferase assay demonstrates that all three CRTCs
induce PII activity in vitro and that LKB1 significantly
suppresses the CRTC-dependent activation of aromatase
PII. CRTC2 staining was absent from testicular tissue bi-
opsied from both patients and control prepubertal testis
tissue (data not shown) consistent with data from Conk-
right et al (33) demonstrating that CRTC2 mRNA expres-
sion in the testis is low when compared to CRTC1 and
CRTC3. We did not observe a relationship between cy-
Figure 4. Immunostaining for aromatase, LKB1 and CRTC proteins in
PJS breast tissue. (A-D) Immunohistochemistry demonstrating
aromatase staining (brown) in breast tissue from PJS Patient one (A)
compared to female postmenopausal breast tumor (B), non-PJS
gynecomastia (C) and normal female breast (D). Insets represent
negative controls were primary antibody was ommitted, hematoxilin
nuclear stain (blue). (E-H) Multichannel confocal images examining
colocalization of aromatase (red) and LKB1 (E; green), CRTC1 (F;
green), CRTC2 (G; green) and CRTC3 (H; green) in breast tissue of PJS
Patient one. Hoescht nuclear stain (blue).
doi: 10.1210/jc.2013-2291 jcem.endojournals.org 7
toplasmic CRTC1 staining and aromatase in Patient two.
In vitro reporter assays demonstrated that CRTC1 caused
the lowest fold induction to promoter PII compared to
other CRTCs. CRTC3, on the other hand, potently stim-
ulated PII activity in vitro and, consistent with these find-
ings there was increased cytoplasmic staining for CRTC3
colocalized with intense aromatase staining within abnor-
mal cords of both patients. Conversely, cells which had
low to undetectable levels of aromatase had low nuclear
staining for CRTC3. In the breast, all three CRTCs were
detectable and their nuclear localization was positively
correlated with aromatase immunoreactivity. Our previ-
ous work in the breast also demonstrated that CRTC over-
expression was associated with an increase in aromatase
transcript expression, whereas knockdown of CRTCs is
sufficient to decrease aromatase activity in breast stromal
cells (34).
Taken together, our results suggest that the normal al-
lele of STK11 in PJS patients encodes a protein capable of
causing CRTC cytoplasmic sequestration and as a result
inhibits aromatase expression (Figure 5). Loss of LKB1
expression is then associated with an increase in CRTC
nuclear localization and aromatase expression and hence
estrogen biosynthesis in the testis and breast. This is the
first report to describe a mechanism whereby loss of LKB1
is associated with development of breast tissue in the pre-
pubertal male.
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